Company Overview
About Synchron
Synchron is a neurotechnology company developing brain-computer interface (BCI) technology using a minimally invasive endovascular surgical approach. Unlike conventional BCIs that require open-brain surgery to implant electrode arrays directly on the cortex, Synchron's Stentrode device is delivered through a catheter inserted via the jugular vein and positioned in a blood vessel adjacent to the motor cortex — requiring no open neurosurgery and dramatically reducing patient risk and recovery time. The Stentrode detects neural signals associated with intended movement and translates them into digital commands, enabling individuals with severe paralysis — from ALS, stroke, or spinal cord injury — to control computers, smartphones, and other devices using thought alone.
Business Model & Competitive Advantage
Synchron raised a $200M Series D in November 2025, bringing total funding to $345M. The round was led by Double Point Ventures with participation from ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS, the Australian National Reconstruction Fund, T.Rx Capital, Qatar Investment Authority, K5 Global, Protocol Labs, and IQT. The funding will accelerate pivotal clinical trials and prepare Synchron's first-generation Stentrode for commercial launch, alongside development of a next-generation BCI. Synchron has implanted Stentrode devices in 10 patients across clinical trials in the United States and Australia.
Competitive Landscape 2025–2026
In a landmark milestone, Synchron became the first BCI company to integrate Apple's BCI Human Interface Device (BCI-HID) protocol, co-developing a Bluetooth-based iOS standard that connects Stentrode neural signals directly to iPhone, iPad, and Apple Vision Pro via Switch Control — enabling paralyzed patients to use Apple's ecosystem natively. The company operates a growing Cognitive AI division in New York City focused on training models that decode thought in real time from brain data, and a new engineering hub in San Diego advancing BCI hardware. Synchron represents the leading endovascular BCI approach globally, competing with Neuralink's implanted electrode array on a fundamentally different surgical risk profile.
Key Differentiators
Strong Challenger
Synchron is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Synchron with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Synchron? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Synchron Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Synchron vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →